Shares of FibroGen Inc (NASDAQ:FGEN) have been assigned a consensus rating of “Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $57.00.
FGEN has been the topic of a number of research analyst reports. Mizuho reaffirmed a “buy” rating and set a $72.00 target price on shares of FibroGen in a report on Monday, November 18th. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. BidaskClub cut shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. Finally, Zacks Investment Research cut shares of FibroGen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 14th.
Shares of FGEN stock traded down $0.46 during mid-day trading on Tuesday, hitting $42.05. 671,623 shares of the stock traded hands, compared to its average volume of 554,368. FibroGen has a twelve month low of $32.33 and a twelve month high of $61.23. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of -40.83 and a beta of 1.86. The company’s 50-day simple moving average is $44.33 and its 200-day simple moving average is $42.60. The company has a debt-to-equity ratio of 0.07, a quick ratio of 8.95 and a current ratio of 9.01.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.02. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The business had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. Analysts forecast that FibroGen will post -0.16 earnings per share for the current year.
In related news, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $38.27, for a total value of $229,620.00. Following the transaction, the director now owns 34,400 shares of the company’s stock, valued at approximately $1,316,488. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider K Peony Yu sold 3,420 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $46.68, for a total value of $159,645.60. Following the sale, the insider now owns 172,617 shares in the company, valued at approximately $8,057,761.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,295 shares of company stock valued at $1,632,226. Corporate insiders own 8.96% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in FGEN. Barclays PLC raised its holdings in shares of FibroGen by 36.1% during the third quarter. Barclays PLC now owns 153,930 shares of the biopharmaceutical company’s stock valued at $5,692,000 after acquiring an additional 40,798 shares during the period. Hillhouse Capital Advisors LTD. grew its position in FibroGen by 36.0% during the 2nd quarter. Hillhouse Capital Advisors LTD. now owns 2,724,519 shares of the biopharmaceutical company’s stock worth $123,094,000 after purchasing an additional 721,232 shares in the last quarter. Doheny Asset Management CA raised its stake in FibroGen by 1.6% during the 2nd quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock valued at $1,648,000 after purchasing an additional 586 shares during the period. HighTower Advisors LLC raised its stake in FibroGen by 67.5% during the 2nd quarter. HighTower Advisors LLC now owns 43,040 shares of the biopharmaceutical company’s stock valued at $1,945,000 after purchasing an additional 17,351 shares during the period. Finally, BlackRock Inc. raised its stake in FibroGen by 1.0% during the 2nd quarter. BlackRock Inc. now owns 6,233,136 shares of the biopharmaceutical company’s stock valued at $281,613,000 after purchasing an additional 60,249 shares during the period. Institutional investors own 68.71% of the company’s stock.
About FibroGen
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Further Reading: What is the Dividend Aristocrat Index?
-